Spots Global Cancer Trial Database for A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
Official Title: A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Study ID: NCT01004224
Interventions
Study Description
Brief Summary: The study will determine the maximum tolerated dose and thus the recommended phase II dose and schedule of the compound and characterize the safety.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Novartis Investigative Site, Duarte, California, United States
Novartis Investigative Site, Los Angeles, California, United States
Novartis Investigative Site, Los Angeles, California, United States
University of Colorado Dept. of Anschutz Cancer (3), Aurora, Colorado, United States
Novartis Investigative Site, New Haven, Connecticut, United States
Novartis Investigative Site, Boston, Massachusetts, United States
Novartis Investigative Site, Detroit, Michigan, United States
Memorial Sloan Kettering Cancer Center Onc. Dept.., New York, New York, United States
Novartis Investigative Site, New York, New York, United States
Novartis Investigative Site, Columbus, Ohio, United States
Novartis Investigative Site, Philadelphia, Pennsylvania, United States
Thomas Jefferson University Hospital Onc Dept, Philadelphia, Pennsylvania, United States
Novartis Investigative Site, Pittsburgh, Pennsylvania, United States
Novartis Investigative Site, Memphis, Tennessee, United States
Novartis Investigative Site, Nashville, Tennessee, United States
Novartis Investigative Site, Salt Lake City, Utah, United States
Novartis Investigative Site, Heidelberg, Victoria, Australia
Novartis Investigative Site, Vienna, , Austria
Novartis Investigative Site, Bordeaux Cedex, , France
Novartis Investigative Site, Lyon Cedex, , France
Novartis Investigative Site, Marseille, , France
Novartis Investigative Site, Montpellier Cedex 5, , France
Novartis Investigative Site, Paris, , France
Novartis Investigative Site, Saint-Herblain Cédex, , France
Novartis Investigative Site, Suresnes, , France
Novartis Investigative Site, Toulouse Cedex 9, , France
Novartis Investigative Site, Villejuif Cedex, , France
Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany
Novartis Investigative Site, Essen, , Germany
Novartis Investigative Site, Hannover, , Germany
Novartis Investigative Site, Marburg, , Germany
Novartis Investigative Site, Ramat Gan, , Israel
Novartis Investigative Site, Tel Aviv, , Israel
Novartis Investigative Site, Meldola, FC, Italy
Novartis Investigative Site, Seoul, Korea, Korea, Republic of
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Amsterdam, , Netherlands
Novartis Investigative Site, Amsterdam, , Netherlands
Novartis Investigative Site, Singapore, , Singapore
Novartis Investigative Site, Sevilla, Andalucia, Spain
Novartis Investigative Site, Barcelona, Catalunya, Spain
Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain
Novartis Investigative Site, Barcelona, , Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Taipei, , Taiwan
Novartis Investigative Site, Bangkok, , Thailand
Novartis Investigative Site, Chiang Mai, , Thailand
Novartis Investigative Site, Izmir, , Turkey
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
